463
Views
6
CrossRef citations to date
0
Altmetric
Review

Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options

, &
Pages 965-973 | Received 31 Mar 2021, Accepted 09 Jul 2021, Published online: 19 Jul 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Massimo Offidani, Laura Corvatta, Sonia Morè, Maria Valentina Manieri & Attilio Olivieri. (2022) An update on novel multiple myeloma targets. Expert Review of Hematology 15:6, pages 519-537.
Read now
Alessandro Rizzo, Antonio Cusmai, Gennaro Gadaleta-Caldarola & Gennaro Palmiotti. (2022) Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?. Expert Review of Gastroenterology & Hepatology 16:4, pages 333-339.
Read now
Alessandro Rizzo & Angela Dalia Ricci. (2022) Predictors of response for hepatocellular carcinoma immunotherapy: is there anything on the horizon?. Expert Review of Precision Medicine and Drug Development 7:1, pages 50-57.
Read now

Articles from other publishers (3)

Weam Othman Elbezanti, Kishore B. Challagundla, Subash C. Jonnalagadda, Tulin Budak-Alpdogan & Manoj K. Pandey. (2023) Past, Present, and a Glance into the Future of Multiple Myeloma Treatment. Pharmaceuticals 16:3, pages 415.
Crossref
Giuseppe Bertuglia, Lorenzo Cani, Alessandra Larocca, Francesca Gay & Mattia D’Agostino. (2022) Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?. International Journal of Molecular Sciences 23:24, pages 15879.
Crossref
Rosario Hervás-Salcedo & Beatriz Martín-Antonio. (2022) A Journey through the Inter-Cellular Interactions in the Bone Marrow in Multiple Myeloma: Implications for the Next Generation of Treatments. Cancers 14:15, pages 3796.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.